Pipeline of Proprietary Solutions

RI-002, our lead product candidate, is derived from tailored immune globulin pools and targets the unmet needs of immunodeficient patients. Through our proprietary immunotechnology platform, donors with high-titer antibodies were screened and identified. RI-002 demonstrated positive Phase III results, successfully meeting its primary end point of preventing serious bacterial infections such as bacterial pneumonia, osteomyelitis, and bacterial sepsis in immunocompromised patients with Primary Immunodeficiency Diseases (PIDD). The majority of patients in this study did not experience any infusion-related AEs or complications. There were no SAEs reported during the trial attributable to the study drug. There was a low incidence of adverse infusion reactions, with a total of 31 events experienced by 18 patients.